治疗视网膜分支静脉阻塞及继发黄斑水肿药物研究进展  

Advances in drug therapy for branch retinal vein occlusion

作　　者：杨玉畅 白杰 胡盼祥 刘曼婷 史文娟 朱倩 刘娟[1] 谢立科[2] 郝晓凤[2] 曲昌海[1] YANG Yu-chang;BAI Jie;HU Pan-xiang;LIU Man-ting;SHI Wen-juan;ZHU Qian;LIU Juan;XIE Li-ke;HAO Xiao-feng;QU Chang-hai(School of Chinese Materia Medica,Beijing University of Chinese Medicine,Beijing 102488;Eye Hospital,Chinese Academy of Traditional Chinese Medicine,Beijing 100040)

机构地区：[1]北京中医药大学中药学院,北京102488 [2]中国中医科学院眼科医院,北京100040

出　　处：《中南药学》2024年第8期2144-2148,共5页Central South Pharmacy

基　　金：北京市自然科学基金面上项目(No.7202123)。

摘　　要：视网膜分支静脉阻塞(BRVO)为临床常见眼科疾病,会对患者视力造成不可逆的损伤,严重威胁人类生命健康。黄斑水肿(ME)为BRVO常见继发症,目前尚无特效药物针对治疗,因此对BRVO及继发ME相关治疗药物的研究显得尤为重要。本文就近年来治疗BRVO和继发ME的药物研究最新进展进行综述。Branch retinal vein occlusion(BRVO)is a prevalent ocular pathology in clinical practice,which may potentially cause irreversible damage upon patients’visual acuity and consequently pose a substantial threat to overall human well-being.Macular edema(ME)emerges as a prevalent sequelae of BRVO,and as of now,there lacks a definitive pharmaceutical intervention for its management.Consequently,development of drugs targeting BRVO and secondary ME matters much.This article comprehensively reviewed the recent advance in pharmaceutical research on the treatment of BRVO and secondary ME.

关 键 词：视网膜分支静脉阻塞 药物治疗 研究进展 血-视网膜屏障 

分 类 号：R774.1[医药卫生—眼科]